Drug Search Results
More Filters [+]

Mequitazine

Alternative Names: mequitazine
Latest Update: 2022-08-29
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: H1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Algeria | Brazil | Chile | Dominican Republic | Egypt | France | Ireland | Italy | Korea | Lebanon | Morocco | New Zealand | Peru | Portugal | Russia | Spain | Taiwan | Tunisia | United Arab Emirates | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Pierre Fabre Laboratories
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Mequitazine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Rhinitis, Allergic, Seasonal|Chikungunya Fever

Phase 2: Overactive Bladder|Asthma|Rhinitis, Allergic, Seasonal

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2013-002517-35

P2

Completed

Asthma

2014-04-22

2008-001860-36

P3

Completed

Rhinitis, Allergic, Seasonal

2013-05-29

2010-024271-10

P2

Terminated

Overactive Bladder

2011-09-14

2006-006165-17

P3

Active, not recruiting

Chikungunya Fever

2007-12-20

Recent News Events